CD22 and neoplasm: This further suggests that sequential administration of bryostatin 1 or a bryolog to enhance the CD22 target density followed by an anti-CD22 CAR T cell infusion could be a viable strategy for clearing CD22lo tumor cells which appear to be driving patient relapse11.